BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-6628 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-6628\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07160179-5184@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:ABBV-6628: Phase 1/2 readout est. (NCT07160179)
DESCRIPTION:ABBV-6628\, phase 1/2\, Age-Related Macular Degeneration.\nStud
 y: Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves
  Through the Body of Adult Participants With Geographic Atrophy Secondary 
 to Age-Related Macular Degeneration\nEstimated primary completion: October
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/abbv-6628#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07160179
URL:https://assetmemo.bio/drug/abbv-6628#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
